Literature DB >> 26668126

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

E Schuler1, A Giagounidis2, D Haase3, K Shirneshan3, G Büsche4, U Platzbecker5, F Nolte6, K Götze7, R F Schlenk8, A Ganser9, A Letsch10, F Braulke3, M Lübbert11, G Bug12, P Schafhausen13, U Bacher3, N Gattermann1, M Wulfert1, R Haas1, U Germing1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26668126     DOI： 10.1038/leu.2015.340

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Authors:  B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors:  Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

3.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

4.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.

Authors:  Friederike Braulke; Klaus Jung; Julie Schanz; Katharina Götze; Catharina Müller-Thomas; Uwe Platzbecker; Ulrich Germing; Tim H Brümmendorf; Gesine Bug; Oliver Ottmann; Aristoteles A N Giagounidis; Michael Stadler; Wolf-Karsten Hofmann; Philippe Schafhausen; Michael Lübbert; Richard F Schlenk; Igor W Blau; Christina Ganster; Sebastian Pfeiffer; Katayoon Shirneshan; Michael Metz; Sven Detken; Jörg Seraphin; Kathleen Jentsch-Ullrich; Angelika Böhme; Burkhard Schmidt; Lorenz Trümper; Detlef Haase
Journal:  Leuk Res       Date:  2013-04-25       Impact factor: 3.156

6.  Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Authors:  S Geyh; S Oz; R-P Cadeddu; J Fröbel; B Brückner; A Kündgen; R Fenk; I Bruns; C Zilkens; D Hermsen; N Gattermann; G Kobbe; U Germing; F Lyko; R Haas; T Schroeder
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

7.  Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.

Authors:  M Mallo; J Cervera; J Schanz; E Such; G García-Manero; E Luño; C Steidl; B Espinet; T Vallespí; U Germing; S Blum; K Ohyashiki; J Grau; M Pfeilstöcker; J M Hernández; T Noesslinger; A Giagounidis; C Aul; M J Calasanz; M L Martín; P Valent; R Collado; C Haferlach; C Fonatsch; M Lübbert; R Stauder; B Hildebrandt; O Krieger; C Pedro; L Arenillas; M Á Sanz; A Valencia; L Florensa; G F Sanz; D Haase; F Solé
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

8.  Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.

Authors:  Michael Wulfert; Anna C Küpper; Christoph Tapprich; Sylvia S Bottomley; David Bowen; Ulrich Germing; Rainer Haas; Norbert Gattermann
Journal:  Exp Hematol       Date:  2008-05       Impact factor: 3.084

9.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Authors:  A A N Giagounidis; U Germing; S Haase; B Hildebrandt; B Schlegelberger; C Schoch; L Wilkens; M Heinsch; H Willems; M Aivado; C Aul
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

10.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Authors:  A Kuendgen; M Lauseker; A F List; P Fenaux; A A Giagounidis; N A Brandenburg; J Backstrom; A Glasmacher; J Hasford; U Germing
Journal:  Leukemia       Date:  2012-12-21       Impact factor: 11.528
View more
  6 in total

Review 1.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).

Authors:  M Mossner; J-C Jann; D Nowak; U Platzbecker; A Giagounidis; K Götze; A Letsch; D Haase; K Shirneshan; F Braulke; R F Schlenk; T Haferlach; P Schafhausen; G Bug; M Lübbert; A Ganser; G Büsche; E Schuler; V Nowak; J Pressler; J Obländer; S Fey; N Müller; E Lauinger-Lörsch; G Metzgeroth; C Weiß; W-K Hofmann; U Germing; F Nolte
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

3.  Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

Authors:  Anna Hecht; Julia A Meyer; Johann-Christoph Jann; Katja Sockel; Aristoteles Giagounidis; Katharina S Götze; Anne Letsch; Detlef Haase; Richard F Schlenk; Torsten Haferlach; Philippe Schafhausen; Gesine Bug; Michael Lübbert; Felicitas Thol; Guntram Büsche; Esther Schuler; Verena Nowak; Julia Obländer; Stephanie Fey; Nadine Müller; Georgia Metzgeroth; Wolf-Karsten Hofmann; Ulrich Germing; Florian Nolte; Mark Reinwald; Daniel Nowak
Journal:  Ann Hematol       Date:  2021-04-27       Impact factor: 3.673

4.  Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.

Authors:  Johann-Christoph Jann; Daniel Nowak; Florian Nolte; Stephanie Fey; Verena Nowak; Julia Obländer; Jovita Pressler; Iris Palme; Christina Xanthopoulos; Alice Fabarius; Uwe Platzbecker; Aristoteles Giagounidis; Katharina Götze; Anne Letsch; Detlef Haase; Richard Schlenk; Gesine Bug; Michael Lübbert; Arnold Ganser; Ulrich Germing; Claudia Haferlach; Wolf-Karsten Hofmann; Maximilian Mossner
Journal:  J Med Genet       Date:  2017-06-09       Impact factor: 6.318

5.  Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Authors:  Thorben Mährle; Nuray Akyüz; Pim Fuchs; Nicola Bonzanni; Donjete Simnica; Ulrich Germing; Anne Marie Asemissen; Johann Christoph Jann; Florian Nolte; Wolf-Karsten Hofmann; Daniel Nowak; Mascha Binder
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

Review 6.  Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.

Authors:  Ulrich Germing; Ester N Oliva; Devendra Hiwase; Antonio Almeida
Journal:  Hemasphere       Date:  2019-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.